

[Go to Product page](#)

Datasheet for ABIN2666903 CCL25 Protein (AA 24-150)

Overview

Quantity:	10 µg
Target:	CCL25
Protein Characteristics:	AA 24-150
Origin:	Human
Source:	Escherichia coli (E. coli)
Protein Type:	Recombinant
Biological Activity:	Active
Application:	Flow Cytometry (FACS)

Product Details

Purity:	> 98 % , as determined by Coomassie stained SDS-PAGE.
Sterility:	0.22 µm filtered
Endotoxin Level:	Less than 0.01 ng per µg cytokine as determined by the LAL method.

Target Details

Target:	CCL25
Alternative Name:	CCL25 (CCL25 Products)
Background:	CCL25 (TECK) binds to CCR9, the only known receptor for TECK. CCR9 is expressed by a small population of circulating memory CD4+ and CD8+ lymphocytes expressing the intestinal homing receptor α4β7. Therefore, CCL25 is a key regulator for CCR9+CD4+ α4β7 T cell homing to the small intestine. In addition, CCL25 induces adhesion of CD103+ (αEβ7) on CD8

Target Details

intraepithelial lymphocytes to its epithelial ligand E-cadherin. In inflammatory bowel diseases (IBD), as in celiac and Crohn's diseases, the proportion of CCR9+ cells in the peripheral blood and in the gut seems to be inverted, there is a lower frequency of CCR9+CD4+ T cells in the gut mucosa than in the peripheral blood. Also, a decrease in CCR9+CD4+ T cells occurs in the gut of HIV-infected patients. This decrease correlates with a lower expression of CCL25 by inflamed gut endothelial cells. Unusual expression of CCL25 in the liver occurs in primary sclerosis cholangitis (extra-intestinal complication of IBD). In this way, human T cells activated in the gut can be recruited to liver endothelium. Functional expression of CCR9 has been detected in melanoma derived cells, and it has been associated to small intestine metastatic melanoma processes. In addition, CCR9 is expressed by ovarian, breast, and prostate cancer cells.

Molecular Weight:	The 128 amino acid recombinant protein has a predicted molecular mass of approximately 14.3 kDa. The DTT-reduced and non-reduced protein migrate at approximately 16 and 17 kDa by SDS-PAGE respectively. The N-terminal amino acid is Met.
-------------------	---

Application Details

Application Notes:	Optimal working dilution should be determined by the investigator.
Comment:	Biological activity: Bioactivity was measured by its property to chemoattract BaF3-hCCR9 transfectants in a dose dependent manner.
Restrictions:	For Research Use only

Handling

Format:	Liquid
Reconstitution:	For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 µg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.
Buffer:	0.22 µm filtered protein solution is in PBS.
Handling Advice:	Avoid repeated freeze/thaw cycles.
Storage:	-20 °C
Storage Comment:	Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.